[The revolution of AI in drug development]

Philippe Moingeon,Christiane Garbay,Muriel Dahan,Irène Fermont,Ali Benmakhlouf,Alain Gouyette,Pierre Poitou,Alain Saint-Pierre,le Groupe de Veille IA et Sciences pharmaceutiques

DOI: https://doi.org/10.1051/medsci/2024028

Abstract:Artificial intelligence and machine learning enable the construction of predictive models, which are currently used to assist in decision-making throughout the process of drug discovery and development. These computational models can be used to represent the heterogeneity of a disease, identify therapeutic targets, design and optimize drug candidates, and evaluate the efficacy of these drugs on virtual patients or digital twins. By combining detailed patient characteristics with the prediction of potential drug-candidate properties, artificial intelligence promotes the emergence of a "computational" precision medicine, allowing for more personalized treatments, better tailored to patient specificities with the aid of such predictive models. Based on such new capabilities, a mixed reality approach to the development of new drugs is being adopted by the pharmaceutical industry, which integrates the outputs of predictive virtual models with real-world empirical studies.